397 related articles for article (PubMed ID: 25943065)
1. Present status of human papillomavirus vaccine development and implementation.
Herrero R; González P; Markowitz LE
Lancet Oncol; 2015 May; 16(5):e206-16. PubMed ID: 25943065
[TBL] [Abstract][Full Text] [Related]
2. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
4. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.
Lowy DR; Herrero R; Hildesheim A;
Lancet Oncol; 2015 May; 16(5):e226-33. PubMed ID: 25943067
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
6. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
8. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
9. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccines: current status and future prospects.
Garland SM; Smith JS
Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
[TBL] [Abstract][Full Text] [Related]
11. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
12. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
15. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG
Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204
[TBL] [Abstract][Full Text] [Related]
16. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
17. Next generation prophylactic human papillomavirus vaccines.
Schiller JT; Müller M
Lancet Oncol; 2015 May; 16(5):e217-25. PubMed ID: 25943066
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
19. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
20. Current global status & impact of human papillomavirus vaccination: Implications for India.
Sankaranarayanan R; Bhatla N; Basu P
Indian J Med Res; 2016 Aug; 144(2):169-180. PubMed ID: 27934795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
